Boehringer Ingelheim collaborates with Trutino Biosciences

Germany’s Boehringer Ingelheim and privately-held US firm Trutino Biosciences have entered into a research collaboration and worldwide licensing agreement based on Trutino’s innovative On-Demand-Cytokine (ODC) platform.

Under the terms of strategic alliance, family-owned Boehringer Ingelheim gains access to Trutino’s ODC platform technology for the generation and development of up to three new ODC candidates. This new collaboration combines Boehringer Ingelheim’s long-term strategy to provide first-in-class, breakthrough therapies for cancer patients with Trutino’s unique knowledge and expertise in increasing the safety and efficacy of cytokine therapies.

Undisclosed upfront and milestone payments